Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. **(Currently Amended)** A compound of formula (I):



(I)

wherein

A is a cyclic moiety selected from the group consisting of C_{3-14} cycloalkyl, 3-14 membered heterocycloalkyl, C_{4-14} cycloalkenyl, 3-14 membered heterocycloalkenyl, aryl, heteroaryl; the cyclic moiety being optionally substituted with 1-3 substituents, each of which is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, alkylcarbonyloxy, alkyloxycarbonyl, alkylcarbonyl, alkylsulfonylamino, aminosulfonyl, and alkylsulfonyl;

each of X^1 and X^2, independently, is O or S;

Y^1 is $-CH_2-$, -O-, -S-, $-N(R^a)-$, $-N(R^a)-C(O)-O-$, $-O-C(O)-N(R^a)-$, $-N(R^a)-C(O)N(R^b)-$, -O-C(O)-O-, or a bond; each of R^a and R^b, independently being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;

Y^2 is CH_2;

L is an unsaturated C_{4-8} ~~a straight C_{3-12}~~ hydrocarbon chain containing at least one double bond adjacent to Y^1 or Y^2; said unsaturated-hydrocarbon chain being optionally substituted with ~~C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, hydroxyl, halo, amino, nitro,~~ C_{3-5} cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C_{1-4} alkylcarbonyloxy, C_{1-4} alkylcarbonyl, or formyl, $-NH_2$, $-NH(C_{1-2}$ alkyl), or $-N(C_{1-2}$ alkyl$)_2$, or $-N(C_{1-2}$ alkyl$)_2$; ~~and further being optionally interrupted by -O-, -N(R^e)-, -N(R^e)-C(O)-O-, -O-C(O)-(R^e)-, -N(R^e)-C(O)-N(R^d)-, or -O-C(O)-O-; each of R^e and R^d, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;~~ provided that when L contains two or more double bonds, the double bonds are not adjacent to each other; ~~that when L contains three~~

~~double bonds, said hydrocarbon chain is further substituted with C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, hydroxyl, halo, amino, nitro, C_{3-5} cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C_{1-4} alkylcarbonyloxy, C_{1-4} alkylcarbonyl, or formyl; and further provided that when L is C_{3-7} C_{4-7} and contains one triple bond or one or two double bonds and A is phenyl or substituted phenyl, Y^1 is not a bond or $-CH_2-$, and Y^2 is $-CH_2-$; provided that when L is C_4, and A is C_{3-14} cycloalkyl then Y^1 is not CH_2; and further provided that when L is C_4 containing two double bonds, and is ω-substituted with phenyl or substituted phenyl, A is not phenyl or substituted phenyl;~~

or a salt thereof, wherein the compound is not 8-phenyl-5-octenoic acid, 6-phenyl-5-hexenoic acid, 5, 5-diphenylpent-4-enoic acid, 2,2-dichloro-12-phenyl-11-dodecenoic acid, 8-phenyl-6-octenoic acid or 13-phenyl-11-triedecenoic acid.

2. **(Original)** The compound of claim 1, wherein X^1 is O.

3. **(Original)** The compound of claim 1, wherein X^2 is O.

4. **(Original)** The compound of claim 1, where each of X^1 and X^2 is O.

5. **(Previously Presented)** The compound of claim 1, wherein Y^1 is $-CH_2-$, -O-, $-N(R^a)-$, or a bond.

6. **(Canceled)**

7. **(Original)** The compound of claim 1, wherein L is an unsaturated C_{4-8} hydrocarbon containing at least one double bond and no triple bond, said unsaturated hydrocarbon chain being optionally substituted with C_{1-2} alkoxy, hydroxyl, $-NH_2$, $-NH(C_{1-2}$ alkyl), or $-N(C_{1-2}$ alkyl)$_2$, or $-N(C_{1-2}$ alkyl)$_2$.

8. **(Original)** The compound of claim 7, wherein the double bond is in trans configuration.

9-11. **(Canceled)**

12. **(Original)** The compound of claim 1, wherein A is phenyl, naphthyl, indanyl, or tetrahydronaphthyl.

13. **(Previously Presented)** The compound of claim 1, wherein A is phenyl optionally substituted with 1-3 substituents each of which is independently selected from the group consisting of alkyl, alkenyl, hydroxyl, hydroxylalkyl, halo, haloalkyl, and amino.

14-15. **(Canceled)**

16. **(Previously Presented)** The compound of claim 13, wherein L is an unsaturated C_{4-8} hydrocarbon chain containing only double bonds in trans configuration, said unsaturated hydrocarbon chain being optionally substituted with C_{1-2} alkoxy, hydroxyl, $-NH_2$, $-NH(C_{1-2}\text{ alkyl})$, or $-N(C_{1-2}\text{ alkyl})_2$.

17. **(Previously Presented)** The compound of claim 16, wherein X^1 is O; X^2 is O; and Y^1 is $-CH_2-$, -O-, $-N(R^a)-$, or a bond.

18-21. **(Canceled)**

22. **(Currently Amended)** A compound of formula (I):



(I)

wherein

A is a cyclic moiety selected from the group consisting of aryl and heteroaryl; the cyclic moiety being optionally substituted with alkyl, alkenyl, alkynyl, hydroxylalkyl, or amino;

each of X^1 and X^2, independently, is O or S;

Y^1 is $-CH_2-$, -O-, -S-, $-N(R^a)-$, $-N(R^a)-C(O)-O-$, $-O-C(O)-N(R^a)-$, $-N(R^a)-C(O)-N(R^b)-$,

-O-C(O)-O-, or a bond; each of R^a and R^b, independently, being hydrogen, alkyl, hydroxylalkyl, or haloalkyl;

Y^2 is CH_2;

L is an unsaturated C_{4-8} ~~a straight C_{3-12}~~ hydrocarbon chain containing at least one double bond adjacent to Y^1 or Y^2; said unsaturated hydrocarbon chain being optionally substituted with ~~C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, hydroxyl, halo, amino, nitro,~~ C_{3-5} cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C_{1-4} alkylcarbonyloxy, C_{1-4} alkylcarbonyl, or formyl, $-NH_2$, $-NH(C_{1-2}$ alkyl), or $-N(C_{1-2}$ alkyl)$_2$, or $-N(C_{1-2}$ alkyl)$_2$; provided that when L contains two or more double bonds, the double bonds are not adjacent to each other; ~~that when L contains three double bonds, said hydrocarbon chain is substituted with C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, or amino; and further provided that when L is C_{3-7} C_{4-7} and contains one triple bond or one or two double bonds and A is phenyl or substituted phenyl, Y^1 is not a bond or $-CH_2-$, and Y^2 is $-CH_2-$~~;

or a salt thereof, wherein the compound is not 8-phenyl-5-octenoic acid, 6-phenyl-5-hexenoic acid, 5, 5-diphenylpent-4-enoic acid, 2,2-dichloro-12-phenyl-11-dodecenoic acid, 8-phenyl-6-octenoic acid or 13-phenyl-11-triedecenoic acid.

23-24. **(Canceled)**

25. **(Original)** The compound of claim 22, wherein L is an unsaturated C_{4-8} hydrocarbon chain containing only double bonds in trans configuration, said unsaturated hydrocarbon chain being optionally substituted with C_{1-2} alkoxy, hydroxyl, $-NH_2$,
$-NH(C_{1-2}$ alkyl), or $-N(C_{1-2}$ alkyl)$_2$.

26. **(Previously Presented)** The compound of claim 25, where in X^1 is O; X^2 is O; and Y^1 is $-CH_2-$, -O-, $-N(R^a)-$, or a bond.

27-79. **(Canceled)**

80. **(Currently Amended)** A pharmaceutical composition, comprising compound of formula (I):



(I)

wherein

A is a cyclic moiety selected from the group consisting of C_{3-14} cycloalkyl, 3-14 membered heterocycloalkyl, C_{4-14} cycloalkenyl, 3-14 membered heterocycloalkenyl, aryl, and heteroaryl; the cyclic moiety being optionally substituted with 1-3 substituents, each of which is independently selected from the group consisting of alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, alkylcarbonyloxy, alkyloxycarbonyl, alkylcarbonyl, alkylsulfonylamino, aminosulfonyl, and alkylsulfonyl;

each of X^1 and X^2 , independently, is O or S;

Y^1 is $-CH_2-$, -O-, -S-, $-N(R^a)-$, $-N(R^a)-C(O)-O-$, $-O-C(O)-N(R^a)-$, $-N(R^a)-C(O)-N(R^b)-$, -O-C(O)-O-, or a bond; each of R^a and R^b independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;

Y^2 is CH_2;

L is an unsaturated C_{4-8} ~~a straight C_{5-12}~~ hydrocarbon chain containing at least one double bond adjacent to Y^1 or Y^2; said hydrocarbon unsaturated chain being optionally substituted with ~~C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, hydroxyl, halo, amino, nitro,~~ C_{3-5} cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C_{1-4} alkylcarbonyloxy, C_{1-4} alkyloxycarbonyl, C_{1-4} alkylcarbonyl, or formyl -NH(C_{1-2} alkyl), or -N(C_{1-2}alkyl)$_2$, or -N(C_{1-2}alkyl)$_2$, ~~cyano~~; and further being optionally interrupted by ~~-O-, -N(R^e)-,~~ $-N(R^c)-C(O)-O-$, -O-C(O)-$N(R^c)-$, $-N(R^c)-C(O)-N(R^d)-$, or -O-C(O)-O-; each of R^c and R^d, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl; ~~provided that when L is C_4, A is C_{3-14} cycloalkyl then Y_1 is not CH_2; and further provided that when L is C_4 containing two double bonds, and is ω substituted with phenyl or substituted phenyl, A is not phenyl or substituted phenyl; further provided that when L is C_{3-7} C_{5-7} and contains one triple bond or one or two double bonds and A is phenyl or substituted phenyl, Y^1 is not a bond or $-CH_2-$, and Y^2 is $-CH_2-$;~~

or a salt thereof; and

a pharmaceutically acceptable carrier, wherein the compound is not 8-phenyl-5-octenoic acid, 6-phenyl-5-hexenoic acid, 5, 5-diphenylpent-4-enoic acid, 2,2-dichloro-12-phenyl-11-dodecenoic acid, 8-phenyl-6-octenoic acid or 13-phenyl-11-triedecenoic acid.

81. **(Previously Presented)** The pharmaceutical composition of claim 80, wherein X^1 is O.

82. **(Previously Presented)** The pharmaceutical composition of claim 80, wherein X^2 is O.

83. **(Previously Presented)** The pharmaceutical composition of claim 80, where each of X^1 and X^2 is O.

84. **(Previously Presented)** The pharmaceutical composition of claim 80, wherein Y^1 is $-CH_2-$, -O-, $-N(R^a)-$, or a bond.

85. **(Previously Presented)** The pharmaceutical composition of claim 80, wherein L is an unsaturated C_{5-8} hydrocarbon chain containing at least one double bond and no triple bond, said unsaturated hydrocarbon chain being optionally substituted with C_{1-2} alkoxy, hydroxyl, $-NH_2$, $-NH(C_{1-2}$ alkyl), or $-N(C_{1-2}alkyl)_2$, or $-N(C_{1-2}alkyl)_2$.

86. **(Previously Presented)** The pharmaceutical composition of claim 85, wherein the double bond is in trans configuration.

87. **(Previously Presented)** The pharmaceutical composition of claim 80 wherein A is phenyl, naphthyl, indanyl, or tetrahydronaphthyl.

88. **(Previously Presented)** The pharmaceutical composition of claim 80, wherein A is phenyl optionally substituted with 1-3 substituents, each of which is independently selected from the group consisting of alkyl, alkenyl, hydroxyl, hydroxylalkyl, halo, haloalkyl and amino.

89. **(Previously Presented)** The pharmaceutical composition of claim 80, wherein L is an unsaturated C_{5-8} hydrocarbon chain containing only double bonds in trans configuration, said unsaturated hydrocarbon chain being optionally substituted with C_{1-2} alkoxy, hydroxyl, $-NH_2$, $-NH(C_{1-2}$ alkyl), or $-N(C_{1-2}$ alkyl)$_2$.

90. **(Previously Presented)** The pharmaceutical composition of claim 89, wherein X^1 is O; X^2 is O; and Y^1 is $-CH_2-$, -O-, $-N(R^a)-$, or a bond.

91. **(Currently Amended)** A compound of formula (I):



(I)

wherein

A is a cyclic moiety selected from the group consisting of C_{3-14} cycloalkyl, 3-14 membered heterocycloalkyl, C_{4-14} cycloalkenyl, 3-14 membered heterocycloalkenyl, aryl, and heteroaryl; the cyclic moiety being optionally substituted with alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, alkylcarbonyloxy, alkyloxycarbonyl, alkylcarbonyl, alkylsulfonylamino, aminosulfonyl, or alkylsulfonyl;

each of X^1 and X^2, independently, is O or S;

Y^1 is $-CH_2-$, -S-, $-N(R^a)-$, $-N(R^a)-C(O)-O-$, $-O-C(O)-N(R^a)-$, $-N(R^a)-C(O)-N(R^b)-$, -O-C(O)-O-, or a bond; each of R^a and R^b, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;

Y^2 is $-CH_2-$;

L is <u>an unsaturated</u> ~~a straight~~ ~~C_{3-6}~~ <u>C_{4-6}</u> hydrocarbon chain containing at least one double bond adjacent to Y^2; said <u>unsaturated</u> hydrocarbon chain being substituted with ~~C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, amino, nitro,~~ C_{3-5} cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C_{1-4} alkylcarbonyloxy, C_{1-4} alkylcarbonyl, or formyl; and further being optionally interrupted by ~~-O-, $-N(R^e)-$,~~ $-N(R^c)-C(O)-O-$, $-O-C(O)-N(R^c)-$, $-N(R^c)-C(O)-$

$N(R^d)$-, or -O-C(O)-O-; each of R^c and R^d, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;

~~provided that when L is C_4, A is C_{3-14} cycloalkyl then Y_1 is not CH_2; and further provided that when L is C_4 containing two double bonds, and is ω substituted with phenyl or substituted phenyl, A is not phenyl or substituted phenyl; further provided that when L is C_{3-7} C_{4-6} and contains one triple bond or one or two double bonds and A is phenyl or substituted phenyl, Y^1 is not a bond or CH_2, and Y^2 is CH_2;~~

or a salt thereof, wherein the compound is not 5, 5-diphenylpent-4-enoic acid, 8-phenyl-6-octenoic acid or 13-phenyl-11-triedecenoic acid.

92. **(Previously Presented)** The compound of claim 91, wherein X^1 is O.

93. **(Previously Presented)** The compound of claim 91, wherein X^2 is O.

94. **(Previously Presented)** The compound of claim 91, wherein each of X^1 and X^2 is O.

95. **(Canceled)**

96. **(Currently Amended)** The compound of claim 91, wherein ~~L is an unsaturated C_{4-6} hydrocarbon chain containing at least one double bond and no triple bond,~~ said unsaturated hydrocarbon chain being substituted with C_{1-2} alkoxy, $-NH_2$, $-NH(C_{1-2}$ alkyl), $-N(C_{1-2}$ alkyl)$_2$, $-N(C_{1-2}$ alkyl)$_2$, halo, or monocyclic aryl.

97. **(Previously Presented)** The compound of claim 96, wherein said double bond is in trans configuration.

98. **(Canceled)**

99. **(Previously Presented)** The compound of claim 91, wherein A is phenyl optionally substituted with alkyl, alkenyl, hydroxyl, hydroxylalkyl, halo, haloalkyl, or amino.

100. **(Previously Presented)** The compound of claim 91, wherein L is an unsaturated C_{5-6} hydrocarbon chain containing double bonds only in trans configuration, said unsaturated hydrocarbon chain being substituted with C_{1-2} alkoxy, $-NH_2$, $-NH(C_{1-2}$ alkyl), $-N(C_{1-2}$ alkyl$)_2$, halo, or monocyclic aryl.

101. **(Previously Presented)** The compound of claim 100, wherein X^1 is O; X^2 is O; and Y^1 is $-CH_2-$, $-N(R^a)-$, or a bond.

102. **(Currently Amended)** A compound of formula (I):



(I)

wherein

A is a cyclic moiety selected from the group consisting of C_{3-14} cycloalkyl, 3-14 membered heterocycloalkyl, C_{4-14} cycloalkenyl, 3-14 membered heterocycloalkenyl, aryl, a heteroaryl; the cyclic moiety being optionally substituted with alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, hydroxylalkyl, halo, haloalkyl, amino, alkylcarbonyloxy, alkyloxycarbonyl, alkylcarbonyl, alkylsulfonylamino, aminosulfonyl, or alkylsulfonyl;

each of X^1 and X^2, independently, is O or S;

Y^1 is $-CH_2-$, -O-, -S-, $-N(R^a)-$, $-N(R^a)-C(O)-O-$, $-O-C(O)-N(R^a)-$, $-N(R^a)-C(O)-N(R^b)-$, $-O-C(O)-O-$, or a bond; each of R^a and R^b, independently being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;

Y^2 is CH_2;

L is <u>an unsaturated</u> ~~a straight~~ ~~C_{3-7}~~ <u>C_{4-7}</u> hydrocarbon chain ~~optionally~~ containing at least one double bond adjacent to Y^1 or Y^2; said <u>unsaturated</u>~~-~~hydrocarbon chain being optionally substituted with ~~C_{1-4}alkyl, C_{2-4}alkenyl, C_{2-4}alkynyl, C_{1-4}alkoxy, hydroxyl, halo, amino, nitro,~~ C_{3-5} cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C_{1-4}

alkylcarbonyloxy, C_{1-4} alkylcarbonyl, or formyl; ~~and further being optionally interrupted by -O-, -N(R^e)-, -N(R^e)-C(O)-O-, -O-C(O)-N(R^e)-, or -O-C(O)-O-; each of R^e and R^d, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;~~ provided that when L contains two or more double bonds, the double bonds are not adjacent to each other; ~~that when L contains three double bonds, said hydrocarbon chain is further substituted with C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, hydroxyl, halo, amino, nitro, C_{3-5} cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C_{1-4} alkylcarbonyloxy, C_{1-4} alkylcarbonyl, or formyl; and further provided that when L is C_4 or C_5 C_{3-7} C_{4-7} and contains one triple bond or one or two double bonds and A is phenyl or substituted phenyl, Y^1 is not a bond or -CH_2-, and Y^2 is -CH_2-;~~

~~provided that when L is C_4, A is C_{3-14} cycloalkyl then Y_1 is not CH_2; and further provided that when L is C_4 containing two double bonds, and is ω-substituted with phenyl or substituted phenyl, A is not phenyl or substituted phenyl;~~

or a salt thereof, wherein the compound is not 8-phenyl-5-octenoic acid, 6-phenyl-5-hexenoic acid, or 5, 5-diphenylpent-4-enoic acid.

103. **(Currently Amended)** A compound of formula (I):



(I)

wherein

A is phenyl, naphthyl, indanyl, or tetrahydronaphthyl;

each of X^1 and X^2, independently, is O or S;

Y^1 is -CH_2-, -S-, -N(R^a)-C(O)-O-, -O-C(O)-N(R^a)-, -N(R^a)-C(O)-N(R^b)-, -O-C(O)-O-, or a bond;

each of R^a and R^b, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;

Y^2 is -CH_2-;

L is an unsaturated ~~a straight C_{3-6}~~ C_{4-6} hydrocarbon chain containing at least one double bond

adjacent to Y^1 or Y^2; said unsaturated hydrocarbon chain being substituted with ~~C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} alkoxy, amino, nitro,~~ C_{3-5} cycloalkyl, 3-5 membered heterocycloalkyl, monocyclic aryl, 5-6 membered heteroaryl, C_{1-4} alkylcarbonyloxy, C_{1-4} alkyloxycarbonyl, C_{1-4} alkylcarbonyl, or formyl; ~~and further being optionally interrupted by -O-, -N(R^e)-, -N(R^e)-C(O)-O-, -O-C(O)-N(R^e)-, -N(R^e)-C(O)-N(R^d)-, or -O-C(O)-O-; each of R^e and R^d, independently, being hydrogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxylalkyl, hydroxyl, or haloalkyl;~~

~~provided that when L is C_4, A is C_{3-14} cycloalkyl then Y_1 is not CH_2; and further provided that when L is C_4 containing two double bonds, and is ω-substituted with phenyl or substituted phenyl, A is not phenyl or substituted phenyl; further provided that when L is C_{3-7} and contains one triple bond or one or two double bonds and A is phenyl or substituted phenyl, Y^1 is not a bond or -CH_2-, and Y^2 is -CH_2-~~;

or a salt thereof, wherein the compound is not 8-phenyl-5-octenoic acid or 5, 5-diphenylpent-4-enoic acid.